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www.sciencedirect.comEDITORIALYesterday, today and tomorrow in Targeted
Temperature Management‘‘Tomorrow and tomorrow and tomorrow,’’ mused Macbeth,1
and indeed we are all interested in tomorrow. Despite the
exponential development of many medical ﬁelds, we, as practi-
tioners, are often faced with the dilemma: what I did for pa-
tients yesterday has been proven to be bad today. Who
knows what tomorrow will bring. . .?
Introduction
The recent publication of two trials relating to the ﬁelds of
Therapeutic Hypothermia (TH) and Targeted Temperature
Management (TTM) has created a great deal of confusion
for Emergency Physicians attempting to practise evidence-
based medicine.2,3 While hypothermia was considered to be
the gold standard, it is likely that prevention of hyperthermia
was more important. So what is the impact of the new studies
on our practice, and what are the ramiﬁcations in resource-
poor settings?
Yesterday and today
Following extensive animal modelling in the 1960s, Safar et al.
pioneered the concept of induced hypothermia following car-
diac arrest.4 However, it was not until the publication of three
landmark trials early in the 21st century that TH was consid-
ered not only a viable therapeutic modality, but rather an
absolute necessity. In 2001, Idrissi et al. performed a small sin-
gle-centre study using TH for out-of-hospital pulseless electri-
cal activity (PEA) or asystole and demonstrated a staggering
four times improvement in survival to hospital discharge with
a favourable neurological outcome. These results did not meet
statistical signiﬁcance due to the small size of the trial.5 In
2002, Holzer et al. published the now infamous HACA trial
– a large multi-centre trial using TH for out-of-hospital ven-
tricular ﬁbrillation (VF). The authors demonstrated not onlyPeer review under responsibility of African Federation for Emergency
Medicine.
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pital discharge with a favourable neurological outcome, but
also that this advantage was maintained six months later.6 Ber-
nard et al. published a small multi-centre trial focusing on TH
following out-of-hospital VF in the same year. They, too, dem-
onstrated the statistically signiﬁcant improvement in survival
rates at hospital discharge with a favourable neurological out-
come in the hypothermic group.7
The International Liaison Committee on Resuscitation (IL-
COR) published an advisory statement in 2003 that uncon-
scious patients with return of spontaneous circulation
(ROSC) after out-of-hospital VF cardiac arrest should have
TH at 32–34 C for 12–24 h. They also advised that it may
be of beneﬁt for other cardiac arrest rhythms and for in-hospi-
tal arrests.8 The current American Heart Association (AHA)
and ILCOR guidelines recommend TH as a Class 1 interven-
tion in comatose patients following ROSC after out of hospital
cardiac arrest secondary to VF.9,10 These recommendations
suggest that induced hypothermia may be considered in coma-
tose patients following ROSC after in-hospital cardiac arrest
(any rhythm) and out-of-hospital cardiac arrest (PEA and
asystole).10,11 Furthermore, healthcare providers are advised
to monitor core temperature after ROSC and intervene to pre-
vent hyperthermia – particularly in the ﬁrst 48 h.10,11
Today and tomorrow?
As 21 February 2002 marked the beginning of the TH era, so
the landmark articles from 17 November 2013, 11 years later,
have reinforced the core concepts of TH (control the tempera-
ture and prevent hyperthermia and fever) with the release of
both the TTM trial in the NEJM and the induction of pre-hos-
pital mild hypothermia by Kim in JAMA.2,3
The TTM trial was designed to detect a 20% reduction in
the hazard ratio for death when comparing post-cardiac arrest
induced hypothermia between two different temperatures – 33
and 36 C. They analysed the data of 939 patients who had
ROSC after both shockable and non-shockable rhythms. This
trial showed that there was no statistically signiﬁcant outcome
beneﬁt between the two patient groups and, in fact, demon-
strated possible harm for those patients who were assignedn Federation for Emergency Medicine.
4 Editorialto the lower temperature as they had a higher risk of hypokal-
aemia. Although this trial had a fairly rigorous protocol, some
queries remain:
 While the trial did not demonstrate a 20% reduction in haz-
ard ratio, there may still be a beneﬁt albeit smaller and this
might only be detected if there were larger patient numbers
included in the trial.
 This trial differed substantially from the original trials in
that both patient groups had the intervention and hyper-
thermia was prevented i.e. there was still active manage-
ment of the patients’ temperature. The optimum
temperature target is still unknown.
 In both groups, there was a delay in instituting the interven-
tion. From animal studies,12–14 we know this can be detri-
mental although from the Kim trial, there was no effect
(see below).
 In the 33 C group, re-warming took place at the faster side
of the recommended rewarming rate (0.5 C per hour).
Although there are no studies which have outlined the opti-
mum rewarming rate in cardiac arrest patients, it is plausi-
ble that slow rewarming will better preserve the
neuroprotective effects of hypothermia.15 Therefore a faster
rewarming may also have negatively impacted this group.
In the pre-hospital trial by Kim, where both VF and non-
VF cardiac arrest patients received early induction of mild
hypothermia compared to standard hospital induction, there
was no beneﬁt found with regard to neurological outcomes
or survival. There was, however, potential harm as those pa-
tients receiving the cold intravenous ﬂuids had a higher risk
of re-arrest pre-hospital as well as an increased risk of pulmon-
ary oedema in the ﬁrst 24 h post-admission.
Application in the resource-poor environment
When considering the potential implementation of TTM in re-
source-poor settings, there are several factors that need to be
carefully considered. Firstly, there is no evidence for or against
the use of TTM following cardiac arrest in resource-limited
settings. Indeed, if the evidence for TTM following cardiac ar-
rest is unclear in the best-resourced areas of the world, then the
evidence favouring TTM in low and middle income countries
must be even more uncertain. Furthermore, whether the avail-
able evidence from well-resourced settings can be directly
translated into such different populations is doubtful.
Secondly, TTM must be considered as only one component
of a bundle of elements constituting post-cardiac arrest care.
Unless the other constituents of care can be effectively admin-
istered TTM alone is likely to be of limited beneﬁt, or may
even be harmful. There are basic minimum infrastructure
and stafﬁng requirements that must be fulﬁlled for TTM to
be feasibly implemented. While it is easy to induce hypother-
mia in the ED using one of several available methods (espe-
cially with a target temperature of 36 C), the important part
of TTM is the avoidance of hyperthermia for up to 72 h
post-cooling. This requires intensive resources extending be-
yond the ED.
Clearly the level of resources at any particular facility will
determine whether a post-cardiac arrest TTM programme
should be instituted: If resources in any particular facility are routinely con-
sumed in the management of conditions with similar (or
poorer) prognosis than arrythmogenic cardiac arrest, such
as decompensated heart failure or stage 4 malignancies,
then it is reasonable to motivate strongly for complete
and comprehensive post-cardiac arrest care, including
TTM.
 Generally a hospital below the level of a tertiary or aca-
demic centre will not be able to deliver comprehensive
post-cardiac arrest care since the requirements would
include the availability of technical equipment, an intensive
care unit, specialised imaging facilities, highly differentiated
clinical services and an infrastructure able to complete the
protocol correctly.
It is an important principle that post-cardiac arrest care
must be delivered in every facility where these patients are
seen. Whether this is complex resuscitative care or palliative
care will depend on the available resources and clinical sce-
nario. Every facility should, however, have a written policy
on the palliative care plan for the post-cardiac arrest patient.
The only studies available on TTM in resource-poor set-
tings are those in neonates. While there is some evidence that
TTM can be achieved using inexpensive methods16 there is
no evidence of equivalence. Other studies have either recom-
mended not to use TTM outside academic centres17 or have
yet to produce real results.18
Conclusion
In a resource-rich environment, there is no doubt that TTM is
of beneﬁt for comatose patients following ROSC after cardiac
arrest. It does appear however, that some reﬁnement in proto-
cols is required to optimise patient care. TTM in the resource-
poor environment is not as clear-cut, and needs a careful bal-
ancing act between resources consumed and beneﬁt achieved,
but comprehensive post-cardiac arrest care must be included
if TTM is to be considered. The old bush-medicine lore cer-
tainly applies: do what you can – where you are – with what
you have; but TTM should probably not be prioritised above
other aspects of post-cardiac arrest care.
Oh, and use 36 C rather than 33 C.
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